Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Neoadjuvant radiotherapy and chemotherapy in localy advanced rectal cancer (CROSBI ID 308490)

Prilog u časopisu | izvorni znanstveni rad | domaća recenzija

Fröbe, Ana ; Marić-Brozić, Jasmina ; Soldić, Željko ; Bolanča, Ante ; Zovak, Mario ; Jones, Glenn ; Rosenblatt, Eduardo ; Đaković, Nikola Neoadjuvant radiotherapy and chemotherapy in localy advanced rectal cancer // Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti, 530 (2017), 44; 89-101. doi: 10.21857/yvjrdcn3zy

Podaci o odgovornosti

Fröbe, Ana ; Marić-Brozić, Jasmina ; Soldić, Željko ; Bolanča, Ante ; Zovak, Mario ; Jones, Glenn ; Rosenblatt, Eduardo ; Đaković, Nikola

hrvatski

Neoadjuvant radiotherapy and chemotherapy in localy advanced rectal cancer

At the Department of Oncology and Nuclear Medicine UHC “Sestre milosrdnice” patients who had advanced rectal cancer were treated with preoperative radiotherapy and chemotherapy, in cooperation with the IAEA and ESTRO. Fifteen patients who met the criteria and signed informed consent were included. Patients were randomized into two groups: Group 1: standard group, neoadjuvant approach (chemotherapy 5-FU / leucovorin concomitantly with radiotherapy (45-50 Gy in 25 fractions) ; Group 2: short course group, chemotherapy 5-FU / leucovorin with radiotherapy (25 Gy in 5 fractions). The main objectives were to determine the rate of resectability after completion of neoadjuvant therapy and to determine the percentage of local control and overall survival.

neoadjuvant therapy ; locally advanced rectal cancer

nije evidentirano

engleski

Neoadjuvant radiotherapy and chemotherapy in localy advanced rectal cancer

At the Department of Oncology and Nuclear Medicine UHC “Sestre milosrdnice” patients who had advanced rectal cancer were treated with preoperative radiotherapy and chemotherapy, in cooperation with the IAEA and ESTRO. Fifteen patients who met the criteria and signed informed consent were included. Patients were randomized into two groups: Group 1: standard group, neoadjuvant approach (chemotherapy 5-FU / leucovorin concomitantly with radiotherapy (45-50 Gy in 25 fractions) ; Group 2: short course group, chemotherapy 5-FU / leucovorin with radiotherapy (25 Gy in 5 fractions). The main objectives were to determine the rate of resectability after completion of neoadjuvant therapy and to determine the percentage of local control and overall survival.

neoadjuvant therapy ; locally advanced rectal cancer

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

530 (44)

2017.

89-101

objavljeno

1330-5301

1848-641X

10.21857/yvjrdcn3zy

Povezanost rada

Kliničke medicinske znanosti, Temeljne medicinske znanosti

Poveznice